Patient enrollment has been completed in a phase 3 trial of the ranibizumab Port Delivery System for wet age-related macular degeneration, Genentech and Roche announced.
The randomized, multicenter, visual assessor-masked, active comparator-controlled Archway clinical trial is the first phase 3 trial of a device used for the continuous delivery of anti-VEGF therapy.
Patients in the trial’s first arm received the PDS implant with refills of 100 mg/mL ranibizumab at fixed 24-week intervals, while its second arm received monthly intravitreal injections of 0.5 mg ranibizumab.
“Wet AMD is
Uncategorized